Stream
Stories
-
Boehringer Ingelheim posts results of 1-yr Tiotropium/Salmeterol study in COPD
Results for the 220-participant, Phase 3, randomized, triple-masked study were posted on October 29, 2026. The study compared FDC tiotropium/salmeterol with single agents and assessed FEV1, dyspnoea, health status and exacerbations.
-
Veeva Summit showcases AI and data innovations advancing agentic commercial
Veeva Systems announced that leaders from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, and UCB will share strategies at the Veeva Commercial Summit, Europe, 18-19 November in Copenhagen. Attendees will hear how industry-specific AI is enabling sales, marketing, and medical teams to improve customer engagement, uncover valuable insights, and accelerate compliant content delivery.
-
Talazoparib plus enzalutamide versus placebo in metastatic APMR prostate cancer
The authors reported that 805 patients were enrolled in the TALAPRO-2 phase 3 trial, with 402 assigned to talazoparib plus enzalutamide and 403 to placebo plus enzalutamide. Median follow-up for radiographic progression-free survival was 24·9 months for the talazoparib group and 24·6 months for the placebo group.
-
CMS finalizes 2027 ESRD PPS rule with $297.52 base rate
On Oct. 28, 2026, CMS issued a final rule that sets the 2027 ESRD PPS base rate at $297.52, an increase of $15.81 from the 2026 rate, and projects a 2.7% rise in total payments to about 7,600 facilities. The rule also updates phosphate binder inclusion, low-volume and pediatric payment adjustments, and the home and self-dialysis training add-on payment.
-
Ray Therapeutics registers Phase 2/3 trial of RTx-015 in retinitis pigmentosa
The study plans to enroll 60 participants and is expected to start in October 2026, with primary completion projected for October 2028. It aims to evaluate the effectiveness and safety of a single intravitreal injection of the investigational gene therapy RTx-015 in participants with retinitis pigmentosa.
-
Biohaven registers Phase 2b/3 study of BHV-1300 in Graves' Disease
The study, led by Biohaven Therapeutics Ltd., plans to enroll an estimate of 356 participants to evaluate the safety and tolerability of BHV-1300 in adults with Graves' Disease. It plans to start in October 2026 and reach primary completion in December 2028.
-
Precigen registers Phase 3 study of zopapogene imadenovec in pediatric RRP
The study, led by Precigen, Inc., plans to enroll 15 participants and has a planned start date of December 31, 2026, with a planned primary completion date of January 2029. It plans to assess the safety and efficacy of zopapogene imadenovec, an investigational immunotherapy, in children with recurrent respiratory papillomatosis.
-
Hoffmann-La Roche posts results of Phase III astegolimab trial in COPD
The study enrolled 1380 participants and completed primary data collection on June 24, 2025. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
DBV Technologies posts results of Phase 3 DBV712 study in peanut-allergic children
The study, completed with 304 participants, posted results on ClinicalTrials.gov on October 28, 2026. It was an open-label extension of the EPITOPE study evaluating long-term clinical benefit and safety of DBV712 in peanut-allergic children.
-
Bausch Health posts results of Phase 3 rifaximin SSD study in cirrhosis
The study, completed in February 2026, enrolled 517 participants and evaluated rifaximin SSD-40mg IR for delaying the first episode of overt hepatic encephalopathy in patients with liver cirrhosis. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
Amgen posts results of Phase 3 erenumab trial in pediatric chronic migraine
The study, completed with 284 participants, evaluated erenumab in children 6 to <12 years and adolescents 12 to <18 years with chronic migraine. Results were first posted on ClinicalTrials.gov on October 28, 2026.
-
Apellis posts results of Phase 3 extension study of pegcetacoplan in geographic atrophy
The study enrolled 792 participants and completed primary data collection on September 5, 2025. Results were first posted on ClinicalTrials.gov on October 28, 2026.